Christian Sirrenberg

Merck (Germany) — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index2.0kcitations31works3.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer therapeutics and mechanisms(8), DNA Repair Mechanisms(7), Computational Drug Discovery Methods(6), Cancer-related Molecular Pathways(6), Protease and Inhibitor Mechanisms(5)

Publications31 total

DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of<sup>177</sup>Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma
Journal of Nuclear Medicine·2025· 4 citedOpen Access
Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models
International Journal of Molecular Sciences·2024· 3 citedOpen Access
Selective Wee1 Inhibitors Led to Antitumor Activity <i>In Vitro</i> and Correlated with Myelosuppression
ACS Medicinal Chemistry Letters·2023· 17 citedOpen Access
Abstract 6215: Peposertib, a DNA-PK inhibitor, enhances the antitumor efficacy of anthracyclines in triple-negative breast cancer models in vitro and in vivo
Cancer Research·2023· 2 cited
Supplementary Tables 1-2 and Supplementary Figures 1-6 from Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
2023Open Access
Data from Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
2023Open Access
Data from Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
2023Open Access
Supplementary Tables 1-2 and Supplementary Figures 1-6 from Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
2023Open Access
Supplementary Methods, Tables 1-3 from Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin α&lt;sub&gt;v&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt; in Angiogenesis &lt;i&gt;In vitro&lt;/i&gt;: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and α&lt;sub&gt;v&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt; Are Critical
2023Open Access
Data from Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin α&lt;sub&gt;v&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt; in Angiogenesis &lt;i&gt;In vitro&lt;/i&gt;: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and α&lt;sub&gt;v&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt; Are Critical
2023Open Access
Data from Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin α&lt;sub&gt;v&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt; in Angiogenesis &lt;i&gt;In vitro&lt;/i&gt;: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and α&lt;sub&gt;v&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt; Are Critical
2023Open Access
Supplementary Methods, Tables 1-3 from Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin α&lt;sub&gt;v&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt; in Angiogenesis &lt;i&gt;In vitro&lt;/i&gt;: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and α&lt;sub&gt;v&lt;/sub&gt;β&lt;sub&gt;3&lt;/sub&gt; Are Critical
2023Open Access
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
Molecular Cancer Therapeutics·2020· 159 cited
Abstract 338: A new investigational ATM Inhibitor, M3541, synergistically potentiates fractionated radiotherapy and chemotherapy in cancer cells and animal models
Cancer Research·2018· 10 cited
Protein conformational flexibility modulates kinetics and thermodynamics of drug binding
Nature Communications·2017· 283 citedOpen Access
Abstract 4183: A novel selective DNA-PK inhibitor, M3814, as a potential combination partner of Etoposide and Cisplatin in the therapy of lung cancer
Cancer Research·2017· 5 cited
Abstract 4198: Highly potent and selective DNA-PK inhibitor M3814 with sustainable anti-tumor activity in combination with radiotherapy
Cancer Research·2017· 6 cited
Abstract 1658: M3814, a novel investigational DNA-PK inhibitor: enhancing the effect of fractionated radiotherapy leading to complete regression of tumors in mice
Cancer Research·2016· 21 cited
M3814, a DNA-dependent Protein Kinase Inhibitor (DNA-PKi), Potentiates the Effect of Ionizing Radiation (IR) in Xenotransplanted Tumors in Nude Mice
International Journal of Radiation Oncology*Biology*Physics·2016· 13 citedOpen Access
A Novel Strategy for ADME Screening of Prodrugs: Combined Use of Serum and Hepatocytes to Integrate Bioactivation and Clearance, and Predict Exposure to Both Active and Prodrug to the Systemic Circulation
Journal of Pharmaceutical Sciences·2014· 9 cited
page 1 of 2Next →

Frequent Co-authors

Astrid Zimmermann(15), Frank T. Zenke(13), Heike Dahmen(9), Andree Blaukat(9), Thomas Fuchß(8), Christiane Amendt(8), Thomas Grombacher(7), Hans‐Michael Eggenweiler(6), Ulrich Pehl(6), Hans‐Peter Buchstaller(5), Djordje Müsil(5), Vladimir Kirkin(5), Claudia Wilm(5), Lyubomir T. Vassilev(5), Riccardo E. Nisato(5), Ghamartaj Hosseini(5), Georgina S. Butler(5), Thomas Crabbe(5), Andrew Docherty(5), Matthias Wiesner(5)